ReCOG outlines individualized safety principles for abdominal reirradiation across six clinical scenarios

ReCOG presents six clinical scenarios emphasizing individualized cumulative dose assessment, organ function, and situations where abdominal reirradiation should be withheld.

KEY POINTS

  • The Reirradiation Collaborative Group (ReCOG) developed practical principles for abdominal reirradiation through six illustrative clinical cases. The multidisciplinary panel comprised 18 contributors, including 11 radiation oncologists, six medical physicists, and one scientist. Cases covered urgent hemostatic irradiation, pancreatic and adrenal metastases with partial overlap of previous fields, liver SBRT after prior local treatment, and a patient in whom repeat irradiation was not recommended. The paper provides expert guidance rather than a formal evidence-based guideline or prospective clinical trial.
  • Patient selection should integrate treatment intent, cumulative organ exposure, functional reserve, and available alternatives. The authors recommend individualized assessment of previous treatment plans, disease extent, performance status, organ function, systemic therapies, and previous toxicity. Three-dimensional cumulative EQD2 assessment is generally preferred when clinically meaningful overlap exists, but accurate dose reconstruction may require multiple organ-specific rigid registrations or pragmatic point-dose summation. Deformable registration requires particular caution in the abdomen because of bowel mobility, respiratory motion, surgical changes, and organ deformation.
  • Gastrointestinal serial-organ tolerance is a major determinant of treatment feasibility. In an illustrative pancreatic metastasis case following 30 Gy in ten fractions to a partially overlapping spinal region, the panel considered 20–25 Gy in five fractions for palliation and local control. A commonly used cumulative duodenal objective was approximately 54–55 Gy EQD2₃, while small-bowel objectives discussed elsewhere ranged from 60–70 Gy EQD2₃. These represent examples of institutional expert practice, not universally validated cumulative constraints; target coverage may need to be compromised to protect previously irradiated bowel.
  • Assumptions about tissue recovery can materially change the dose available for reirradiation. In the duodenal example, a previous cumulative exposure of 36 Gy EQD2₃ would leave 18 Gy EQD2₃ under a 54-Gy cumulative objective, equivalent to approximately 15 Gy in five fractions. Applying a hypothetical 20% tissue recovery factor reduced the effective prior contribution to 28.8 Gy EQD2₃, increasing the remaining allowance to 25.2 Gy EQD2₃, or approximately 18.7 Gy in five fractions. The authors emphasize that tissue recovery factors are not universally accepted and vary substantially across institutions.
  • Urgent palliation may justify a different balance between cumulative dose uncertainty and immediate clinical benefit. One case involved recurrent gastroesophageal junction cancer with hematemesis four years after 50.4 Gy in 28 fractions, for which 6–8 Gy in one fraction was proposed for hemostasis. Given the urgent indication and limited life expectancy, the panel considered formal cumulative dose reconstruction unnecessary in that specific scenario, while recommending explicit discussion of gastrointestinal injury risk. This illustrates how treatment intent and prognosis may outweigh theoretical late toxicity concerns without eliminating the need for clinical judgment.
  • Liver and kidney reirradiation require functional assessment in addition to physical dose evaluation. For selected liver cases, the panel discussed a mean dose objective of approximately 28–32 Gy EQD2₂–₃ to functioning uninvolved liver, while kidney evaluation included a mean-dose objective around 18 Gy EQD2₂.₅–₃ and additional sparing of the contralateral kidney. Renal assessment should incorporate estimated glomerular filtration rate, while liver evaluation may use Child–Turcotte–Pugh and ALBI scores. These examples are individualized expert planning approaches, not universally applicable prescription limits or validated measures of cumulative organ tolerance.
  • Anatomical changes and severe organ dysfunction may make treatment inappropriate despite technical feasibility. In one liver SBRT case, prior treatment and ablation were associated with approximately 370 cm³ reduction in liver volume, making conventional deformable dose accumulation unreliable and prompting reliance on anatomical landmarks, fiducials, and previously treated regions. Another patient with multifocal hepatocellular carcinoma, recurrent ascites, deteriorating performance status, and Child–Turcotte–Pugh C11 was not offered additional irradiation. These cases emphasize that advanced planning cannot compensate for severely impaired organ function, while the absence of prospective comparative outcomes limits validation of the proposed strategies.

CLINICAL TAKEAWAY

Abdominal reirradiation requires individualized decisions based on treatment intent, previous dose distributions, organ function, and the reliability of cumulative dose assessment. ReCOG provides practical examples for managing gastrointestinal, hepatic, and renal risks, while emphasizing that some patients should not undergo further irradiation. The proposed approaches represent expert practice principles rather than validated universal dose constraints.

SOURCE

Practical Radiation Oncology

Browse more research Suggest a correction